Business Context and Reporting Period
Company: Atara Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 18, 2019
Reporting Period: The filing provides a financial update regarding the quarter ended June 30, 2019, in connection with an underwritten public offering of common stock.
Key Financial Metrics
Cash and Liquidity: Based on preliminary estimates as of June 30, 2019, the Company expects to report approximately $190.1 million in cash, cash equivalents, and short-term investments. The filing explicitly states that the quarter-end financial close process was not yet completed and these figures are unaudited and subject to change.
Revenue, Profit, and Margins: The filing text does not provide specific values for revenue, net income, operating margins, or cash flow for the period ended June 30, 2019.
Debt: The filing text does not provide specific values regarding outstanding debt obligations.
Material Changes and Offering Details
The primary material event is the execution of an underwriting agreement for a public offering. Key terms include:
- Securities Issued: 6,871,727 shares of Common Stock and pre-funded warrants to purchase up to 2,945,026 shares of Common Stock.
- Offering Price: $15.28 per share of Common Stock and $15.2799 per Pre-Funded Warrant.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 1,472,512 shares of Common Stock.
- Expected Gross Proceeds: Approximately $150.0 million, or $172.5 million if the over-allotment option is exercised in full (before deducting underwriting discounts and expenses).
- Expected Closing Date: July 23, 2019.
Guidance, Outlook, and Risks
Management Commentary: Management noted that financial statements for the quarter ended June 30, 2019, would not be available until after the offering is completed. The cash position disclosed is based on preliminary estimates.
Risks and Contingencies:
- The financial data provided is preliminary, unaudited, and subject to change upon completion of financial statement closing procedures.
- The offering is subject to customary closing conditions.
- Representations and warranties in the Underwriting Agreement are qualified by confidential disclosures exchanged between the parties.
Investor Verification Checklist
- Verify the final audited cash, cash equivalents, and short-term investment balance for the quarter ended June 30, 2019, once the financial close is complete.
- Confirm the final closing date of the offering and whether the underwriters exercised the over-allotment option.
- Review the final prospectus supplement for any updates to the estimated proceeds after deducting underwriting discounts and offering expenses.
- Monitor subsequent filings (e.g., 10-Q) for the official revenue and expense figures for the second quarter of 2019.